Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer - Related Studies

Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

This study has been completed.

Study NCT00004934. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Fallopian Tube Cancer
		Ovarian Cancer
		Peritoneal Cavity Cancer

2	Additional conditions recognized in this trial
		Fallopian Tube Neoplasms
		Ovarian Neoplasms

3	More general conditions related to this trial
		Adnexal Diseases
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Fallopian Tube Diseases
		Genital Diseases, Female
		Genital Neoplasms, Female
		Gonadal Disorders
		Neoplasms
		Neoplasms by Site
		Ovarian Diseases
		Urogenital Neoplasms

4	Interventions listed in this trial
		carboplatin
		epirubicin hydrochloride
		paclitaxel
		conventional surgery

5	Additional drug interventions recognized in this trial
		Epirubicin

6	More general drug interventions related to this trial
		Antibiotics, Antineoplastic
		Antimitotic Agents
		Antineoplastic Agents
		Antineoplastic Agents, Phytogenic
		Mitosis Modulators
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses
		Tubulin Modulators

7	Sponsors listed in this trial
		Nordic Society for Gynaecologic Oncology
		European Organization for Research and Treatment of Cancer
		National Cancer Institute of Canada